Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00423527
Status:
COMPLETED
Last Update Posted:
2009-12-18
First Post:
2007-01-16
Brief Title:
Levetiracetam in Central Pain in Multiple SclerosisMS
Sponsor:
Odense University Hospital
Organization:
Odense University Hospital
Study Overview
Official Title:
Double-blind RandomisedPlacebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple sclerosis is often associated with pain There is no standard treatment of this type of pain Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis This is a randomised double-blind placebo-controlled cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None